Extravasation After [177Lu]Lu-HA-DOTATATE Therapy

被引：1
作者：
de Vries-Huizing, Daphne M. V. [1 ]
Cheung, Zing J. [1 ]
Hendrikx, Jeroen J. M. A. [1 ,2 ]
Donswijk, Maarten L. [1 ]
Versleijen, Michelle W. J. [1 ]
机构：
[1] Netherlands Canc Inst, ENETS Ctr Excellence, Dept Nucl Med, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, ENETS Ctr Excellence, Dept Pharm & Pharmacol, Amsterdam, Netherlands
来源：
CLINICAL NUCLEAR MEDICINE | 2024年 / 49卷 / 05期
关键词：
extravasation; lutetium; neuroendocrine tumors; SPECT imaging; MANAGEMENT;
D O I：
10.1097/RLU.0000000000005137
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide receptor radionuclide therapy. During intravenous infusion of 7.4 GBq [Lu-177]Lu-HA-DOTATATE in the upper right arm, extravasation of the radiopharmaceutical occurred through a displaced intravenous catheter. Planar scintigraphy showed pooling of radioactivity in the right upper arm. After 24 hours, the swelling in the arm was decreased; however, erythema was increased. One week later, symptoms had disappeared, and the patient did not experience any complications during follow-up of 11 months.
引用
收藏
页码：454 / 456
页数：3
相关论文
共 9 条
  • [1] Post-PRRT scans: which scans to make and what to look for
    Aalbersberg, Else A.
    de Vries-Huizing, Daphne M. V.
    Tesselaar, Margot E. T.
    Stokkel, Marcel P. M.
    Versleijen, Michelle W. J.
    [J]. CANCER IMAGING, 2022, 22 (01)
  • [2] Extravasation of [177Lu]Lu-DOTATOC: case report and discussion
    Arveschoug, Anne Kirstine
    Bekker, Anne Charlotte
    Iversen, Peter
    Bluhme, Henrik
    Villadsen, Gerda Elisabeth
    Staanum, Peter Frohlich
    [J]. EJNMMI RESEARCH, 2020, 10 (01)
  • [3] Lutetium-177 Radiopharmeceutical Therapy Extravasation Lessons Learned
    Berry, Kendall
    Kendrick, Jessica
    [J]. HEALTH PHYSICS, 2022, 123 (02): : 160 - 164
  • [4] Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE
    Divband, Ghasemali
    Alavi, Seyed Hootan
    Adinehpour, Zohre
    Kalantari, Forough
    Moghadam, Soroush Zarehparvar
    [J]. NUCLEAR MEDICINE REVIEW, 2022, 25 (02) : 136 - 137
  • [5] A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
    Huizing, Daphne M., V
    Peters, Steffie M. B.
    Versleijen, Michelle W. J.
    Martens, Esther
    Verheij, Marcel
    Sinaasappel, Michiel
    Stokkel, Marcel P. M.
    de Wit-van der Veen, Berlinda J.
    [J]. EJNMMI PHYSICS, 2020, 7 (01)
  • [6] Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation
    Maucherat, Bruno
    Varmenot, Nicolas
    Fleury, Vincent
    Senellart, Helene
    Rousseau, Caroline
    [J]. CLINICAL NUCLEAR MEDICINE, 2021, 46 (02) : 144 - 145
  • [7] Cutaneous Management after Extravasation of High-Concentrated Amino Acid Solution Administered for Renal Protection in PRRT
    Sakulpisuti, Chaninart
    Chamroonrat, Wichana
    Tepmongkol, Supatporn
    [J]. TOMOGRAPHY, 2022, 8 (01) : 356 - 363
  • [8] Tissue dose estimation after extravasation of 177Lu-DOTATATE
    Tylski, Perrine
    Pina-Jomir, Geraldine
    Bournaud-Salinas, Claire
    Jalade, Patrice
    [J]. EJNMMI PHYSICS, 2021, 8 (01)
  • [9] Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review
    van der Pol, Jochem
    Voo, Stefan
    Bucerius, Jan
    Mottaghy, Felix M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (07) : 1234 - 1243
1